Key Insights

Highlights

Treatment Research

5 treatments under study, led by Irinotecan

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03554707Early Phase 1WithdrawnPrimary

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Showing all 1 trials

Research Network

Common Treatments

  • Irinotecan1
  • Sgt531
  • Radiation1
  • Temozolomide1
  • Bevacizumab1

Active Sponsors

  • SynerGene Therapeutics, Inc.1

Top Investigators

Activity Timeline